Platinum(II) complexes with selone ligands and method of use

Patent metadata

Field	Value
Publication number	US-10358456-B2
Application number	US-201815933076-A
Country	US
Kind code	B2
Filing date	Mar 22, 2018
Priority date	Mar 22, 2017
Publication date	Jul 23, 2019
Grant date	Jul 23, 2019

Abstract

Platinum(II) complexes with various selones (L) having the general formula PtL2Cl2 are disclosed. The platinum(II) complexes of the invention inhibit growth of cancer cells in vitro and are useful for treatment of proliferative disorders such as cancers and/or tumors.

First claim

The invention claimed is:

1. A platinum (II) complex of formula PtL 2 Cl 2 , wherein L is of formula Ia, Ib, Ic, or Id:

wherein R 4 and R 4′ are independently hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, phenyl, or benzyl.

2. A method of making the platinum (II) complex of claim 1 , said method comprising:
(a) adding a solution of tetrahaloplatinate (II) in a polar aprotic solvent to a solution of a compound of formula Ia, Ib, Ic, or Id in a solvent under inert gas to form a reaction mixture, and
(b) stirring the reaction mixture to form the platinum (II) complex as a precipitate.

3. The method of claim 2 , further comprising filtering the platinum (II) complex.

4. A pharmaceutical composition comprising the platinum (II) complex of claim 1 ; and a pharmaceutically acceptable carrier and/or excipient.

5. The pharmaceutical composition of claim 4 , which comprises 0.1-400 μM of the platinum (II) complex relative to the total volume of the composition.

6. The pharmaceutical composition of claim 5 , wherein the pharmaceutically acceptable carrier and/or excipient is at least one selected from the group consisting of a buffer, an inorganic salt, a fatty acid, a vegetable oil, a synthetic fatty ester, a surfactant, and a polymer.

7. The pharmaceutical composition of claim 5 , further comprising a chemotherapeutic agent.

8. A method for treating cervical cancer, breast cancer, or both in a subject in need of therapy, the method comprising administering to the subject a sufficient amount of the pharmaceutical composition of claim 4 .

9. The method of claim 8 , wherein 1-300 mg/kg of the platinum (II) complex is administered per body weight of the subject.

10. The method of claim 8 , wherein the subject is a mammal.

Assignees

• Univ King Fahd Pet & Minerals
• Univ King Saud

Inventors

• Isab Anvarhusein A
• Altaf Muhammad
• Alhoshani Ali
• Altoum Ali Osman
• Jomaa Mohammed Yagoub

Classifications

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title

• A61K31/282

  Platinum compounds · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07F15/0093 Primary

  without a metal-carbon linkage · CPC title